ERBB2 and neoplasm: Compared with unmodified macrophage membrane-coated nanocarriers, the GEM@PLGA@HM was demonstrated excellent HER2-targeting ability invitro and invivo and showed significantly increased GEM enrichment at HER2+ cancer cells and tumor sites.